牛磺鹅去氧胆酸 516-35-8 98%胆固醇 胆酸衍生物原料厂家供应
| 中文名 | 牛磺鹅去氧胆酸 |
| 英文名 | 2-{[(3alpha,5beta,7alpha,20xi)-3,7-dihydroxy-24-oxocholan-24-yl]amino}ethanesulfonic acid |
| 别名 | 牛磺鹅去氧胆酸 chuntianran牛磺鹅去氧胆酸 牛磺鹅去氧胆酸标准品 |
| 英文别名 | C05465 2-[4-(3,7-dihydroxy-10,13- Taurochenodeoxycholic acid Taurocholic chenodeoxycholic acid 2-{[(3alpha,5beta,7alpha,20xi)-3,7-dihydroxy-24-oxocholan-24-yl]amino}ethanesulfonic acid 2-(4-(3,7-dihydroxy-10,13-diMethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanaMido)ethanesulfonic acid 2-((R)-4-((3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-Dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethanesulfonic acid 2-[4-(3,7-Dihydroxy-10,13-Dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-Tetradecahydro-1H-Cyclopenta[A]Phenanthren-17-Yl)Pentanoylamino]Ethanesulfonic Acid |
| CAS | 516-35-8 |
| 化学式 | C26H45NO6S |
| 分子量 | 499.7 |
| InChI | InChI=1/C26H45NO6S/c1-16(4-7-23(30)27-12-13-34(31,32)33)19-5-6-20-24-21(9-11-26(19,20)3)25(2)10-8-18(28)14-17(25)15-22(24)29/h16-22,24,28-29H,4-15H2,1-3H3,(H,27,30)(H,31,32,33)/t16?,17-,18+,19+,20-,21-,22+,24-,25-,26+/m0/s1 |
| 密度 | 1.216±0.06 g/cm3(Predicted) |
| 熔点 | 186-200°C |
| 溶解度 | 氯仿，甲醇 |
| 折射率 | 1.552 |
| 酸度系数 | 1.42±0.50(Predicted) |
| 存储条件 | Sealed in dry,Room Temperature |
| 外观 | 固体 |
| 颜色 | White to Pale Beige |
| 物化性质 | 白色结晶体，可溶于甲醇、乙醇、DMSO等有机溶剂，来源于动物胆汁。 |
| MDL号 | MFCD00232922 |
| 体外研究 | Taurochenodeoxycholic acid (12-Deoxycholyltaurine) dramatically improves the apoptosis rate of NR8383 cells in a concentration-dependent manner. In the meantime, Taurochenodeoxycholic acid significantly augments PKC mRNA levels, activities and increases JNK, caspase-3 and caspase-8 mRNA expression levels, activities. |
| 体内研究 | Taurochenodeoxycholic acid (12-Deoxycholyltaurine; 0.05, 0.1g/kg) decreases the pulmonary coefficient in the model mice and reduces the pathological damages on their lungs; it can decrease the expression levels of TNF-α and TIMP-2 in pulmonary tissues in the pulmonary fibrosis mice and has no significant effects on MMP2. Taurochenodeoxycholic acid significantly normalizes the clinical inflammatory parameters, prevented indomethacin-induced increases in the biliary contents of secondary bile acids and hydrophobicity index, and tended to attenuate the intestinal inflammation. Taurochenodeoxycholic acid significantly suppresses paw swelling and polyarthritis index, increases the loss body weight and index of thymus and spleen, and amends radiologic changes in AA rats. The overproduction and mRNA expression of TNF-α, IL-1β and IL-6 are remarkably suppressed in serum and synovium tissue of all TCDCA-treated rats. |
展开全文
相关产品
